Pages that link to "Q27673316"
Jump to navigation
Jump to search
The following pages link to Towards a new tuberculosis drug: pyridomycin - nature's isoniazid (Q27673316):
Displaying 50 items.
- New agents for the treatment of drug-resistant Mycobacterium tuberculosis (Q26751463) (← links)
- The application of tetracyclineregulated gene expression systems in the validation of novel drug targets in Mycobacterium tuberculosis (Q26795478) (← links)
- Whole-genome sequencing targets drug-resistant bacterial infections (Q26799059) (← links)
- Next-generation antimicrobials: from chemical biology to first-in-class drugs (Q26799749) (← links)
- Tuberculosis drug discovery in the post-post-genomic era (Q26864729) (← links)
- Tuberculosis: From an incurable scourge to a curable disease - journey over a millennium (Q26865560) (← links)
- A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA (Q27339306) (← links)
- Learning from the past for TB drug discovery in the future (Q27485405) (← links)
- Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA (Q27687750) (← links)
- Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins (Q27700967) (← links)
- The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis (Q27728459) (← links)
- TB Mobile: a mobile app for anti-tuberculosis molecules with known targets (Q28709353) (← links)
- Design, synthesis and structure-activity relationship study of wollamide B; a new potential anti TB agent. (Q30313238) (← links)
- Discovery of Mycobacterium tuberculosis InhA Inhibitors by Binding Sites Comparison and Ligands Prediction (Q30396236) (← links)
- The Redox State Regulates the Conformation of Rv2466c to Activate the Antitubercular Prodrug TP053. (Q30692645) (← links)
- The phosphatidyl-myo-inositol mannosyltransferase PimA is essential for Mycobacterium tuberculosis growth in vitro and in vivo (Q34297745) (← links)
- The mycobacterial cell envelope-lipids (Q34355375) (← links)
- Lansoprazole is an antituberculous prodrug targeting cytochrome bc1. (Q34484243) (← links)
- Systems-level antimicrobial drug and drug synergy discovery (Q34626969) (← links)
- A phylogeny-based sampling strategy and power calculator informs genome-wide associations study design for microbial pathogens. (Q34636791) (← links)
- Direct inhibitors of InhA are active against Mycobacterium tuberculosis. (Q35247307) (← links)
- Whole-genome sequencing for comparative genomics and de novo genome assembly. (Q35579074) (← links)
- The tuberculosis drug discovery and development pipeline and emerging drug targets (Q35664209) (← links)
- Genetic Approaches to Facilitate Antibacterial Drug Development (Q35795582) (← links)
- Computer-Aided Design of Orally Bioavailable Pyrrolidine Carboxamide Inhibitors of Enoyl-Acyl Carrier Protein Reductase of Mycobacterium tuberculosis with Favorable Pharmacokinetic Profiles (Q35878348) (← links)
- Characterization of Mycolic Acids in Total Fatty Acid Methyl Ester Fractions from Mycobacterium Species by High Resolution MALDI-TOFMS. (Q35906843) (← links)
- New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics (Q36057012) (← links)
- Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis (Q36364079) (← links)
- Back to the future: a new 'old' lead for tuberculosis. (Q36379530) (← links)
- Selectivity of Pyridone- and Diphenyl Ether-Based Inhibitors for the Yersinia pestis FabV Enoyl-ACP Reductase. (Q36951981) (← links)
- Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor (Q37034701) (← links)
- Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis (Q37403156) (← links)
- Novel Pharmacological Activity of Artesunate and Artemisinin: Their Potential as Anti-Tubercular Agents (Q37729940) (← links)
- Emerging trends in the discovery of natural product antibacterials (Q38124531) (← links)
- Tuberculosis drug discovery and emerging targets (Q38219605) (← links)
- Trends in discovery of new drugs for tuberculosis therapy (Q38237221) (← links)
- Mycobacterium tuberculosis evolutionary pathogenesis and its putative impact on drug development (Q38258834) (← links)
- Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities. (Q38535724) (← links)
- RETRACTED: Targeting Mycobacterial Enzymes with Natural Products (Q38600486) (← links)
- Strategies for target identification of antimicrobial natural products (Q38710256) (← links)
- Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis (Q38849126) (← links)
- Micrococcin P1 - A bactericidal thiopeptide active against Mycobacterium tuberculosis (Q39461808) (← links)
- Synthesis and antimycobacterial activity of 2,1'-dihydropyridomycins (Q39779898) (← links)
- Identification of the anti-mycobacterial functional properties of piperidinol derivatives. (Q40333807) (← links)
- Enabling faster Go/No-Go decisions through secondary screens in anti-mycobacterial drug discovery (Q41927049) (← links)
- Strength of selection pressure is an important parameter contributing to the complexity of antibiotic resistance evolution (Q42054011) (← links)
- Addressing the Challenges of Tuberculosis: A Brief Historical Account (Q42369869) (← links)
- Functional Characterization of PyrG, an Unusual Nonribosomal Peptide Synthetase Module from the Pyridomycin Biosynthetic Pathway (Q50511277) (← links)
- Examining the role of protein structural dynamics in drug resistance in Mycobacterium tuberculosis. (Q52331616) (← links)
- Identification of InhA inhibitors: A combination of virtual screening, molecular dynamics simulations and quantum chemical studies. (Q53092961) (← links)